Discover Wellness Today

What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps. The post Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges appeared first on MedCity News.

Here’s what healthcare entities should know about the maturing landscape, what to actually be concerned about, and the next stage of healthcare data evolution as we know it. The post Are We Entering an Interoperability Trust Recession? appeared first on MedCity News.

Juno Bio’s funding was supported by Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator. The post Juno Bio Raises $3.8M to Support Vaginal Health appeared first on MedCity News.

HSS chief digital and information officer Ashis Barad, who has worked on both the payer and provider sides of healthcare AI, thinks the industry’s growing “bot vs. bot” battle over prior authorizations and appeals is driving costs up. To him, the real fix lies in providers and payers sharing data to build more personalized care pathways. The post The ‘Bot Vs. Bot’ Dynamic Between Providers & Payers Is Driving Up Costs for Everyone appeared first on MedCity News.

GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a setback to a program once hoped to yield a new blockbuster product for the company’s respiratory drug portfolio. The post GSK Drug From $2B Deal Sputters in Phase 3 Test in Chronic Cough appeared first on MedCity News.

The opportunity ahead is to treat physician well-being as a core strategic priority, measured with the same rigor and acted upon with the same urgency as any other critical performance domain. The post Why Specialty-Specific Measurement and Intervention Are Essential to Address Healthcare Burnout appeared first on MedCity News.

New 3D printed technology makes lower extremity surgeons architects of restoration, not adaptation. The post Why Settle for Acceptable Versus Optimal Outcomes? appeared first on MedCity News.

The House Ways and Means Committee unanimously advanced a bill to reform Medicare Advantage prior authorization requirements. The post Healthcare Groups Praise Unanimous Committee Approval of MA Prior Auth Bill appeared first on MedCity News.

CMS’ proposed 2027 Physician Fee Schedule would bar Medicare payment for remote monitoring services delivered by third-party vendors, following OIG reports that flagged widespread fraud in the space. The post Why CMS Is Trying to Ban Third-Party Remote Patient Monitoring appeared first on MedCity News.

Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley’s lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant depression. The post Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition appeared first on MedCity News.

This is not an argument against capital in independent medicine. Practices need infrastructure, and physicians have legitimate reasons to seek liquidity. It is an argument that the exit stage carries a risk this market has not yet priced. The post What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook appeared first on MedCity News.

If we do not get this right, we may inadvertently cause a new sarcopenia epidemic while congratulating ourselves on solving obesity. The post GLP-1s Are Working — Now Medicine Needs to Measure What Matters appeared first on MedCity News.

For years, the healthcare industry treated data collection as the main challenge. The next phase is about interpretation, coordination, and operational usability. The post Building AI-Ready Public Health Data Systems for Faster, Safer Decisions appeared first on MedCity News.

Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology. The post ‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1 appeared first on MedCity News.

Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers. The post Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer appeared first on MedCity News.